Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology
ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial lung disease of unknown cause, which predominantly affects elderly men who are current or former smokers. Even though it is an uncommon disease, it is of great importance because of its severity and poor prognosis. In recent decades, several pharmacological treatment modalities have been investigated for the treatment of this disease, and the classic concepts have therefore been revised. The purpose of these guidelines was to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of IPF in Brazil. We sought to provide guidance on the practical issues faced by clinicians in their daily lives. Patients of interest, Intervention to be studied, Comparison of intervention and Outcome of interest (PICO)-style questions were formulated to address aspects related to the use of corticosteroids, N-acetylcysteine, gastroesophageal reflux medications, endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, pirfenidone, and nintedanib. To formulate the PICO questions, a group of Brazilian specialists working in the area was assembled and an extensive review of the literature on the subject was carried out. Previously published systematic reviews with meta-analyses were analyzed for the strength of the compiled evidence, and, on that basis, recommendations were developed by employing the Grading of Recommendations Assessment, Development and Evaluation approach. The authors believe that the present document represents an important advance to be incorporated in the approach to patients with IPF, aiming mainly to improve its management, and can become an auxiliary tool for defining public policies related to IPF.
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Pneumologia e Tisiologia
2020
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132020000200400 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1806-37132020000200400 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1806-371320200002004002020-02-28Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodologyBaddini-Martinez,JoséFerreira,JulianaTanni,SuzanaAlves,Luis RenatoCabral Junior,Benedito FranciscoCarvalho,Carlos Roberto RibeiroCezare,Talita JaconCosta,Claudia Henrique daGazzana,Marcelo BassoJezler,SérgioKairalla,Ronaldo AdibKawano-Dourado,LeticiaLima,Mariana SilvaMancuzo,ElianeMoreira,Maria Auxiliadora CarmoRodrigues,Marcelo PalmeiraRodrigues,Silvia Carla SousaRubin,Adalberto SperbRufino,Rogério LopesSteidle,Leila John MarquesStorrer,KarinBaldi,Bruno Guedes Idiopathic pulmonary fibrosis GRADE approach Pulmonary fibrosis/drug therapy Practice guideline ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial lung disease of unknown cause, which predominantly affects elderly men who are current or former smokers. Even though it is an uncommon disease, it is of great importance because of its severity and poor prognosis. In recent decades, several pharmacological treatment modalities have been investigated for the treatment of this disease, and the classic concepts have therefore been revised. The purpose of these guidelines was to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of IPF in Brazil. We sought to provide guidance on the practical issues faced by clinicians in their daily lives. Patients of interest, Intervention to be studied, Comparison of intervention and Outcome of interest (PICO)-style questions were formulated to address aspects related to the use of corticosteroids, N-acetylcysteine, gastroesophageal reflux medications, endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, pirfenidone, and nintedanib. To formulate the PICO questions, a group of Brazilian specialists working in the area was assembled and an extensive review of the literature on the subject was carried out. Previously published systematic reviews with meta-analyses were analyzed for the strength of the compiled evidence, and, on that basis, recommendations were developed by employing the Grading of Recommendations Assessment, Development and Evaluation approach. The authors believe that the present document represents an important advance to be incorporated in the approach to patients with IPF, aiming mainly to improve its management, and can become an auxiliary tool for defining public policies related to IPF.info:eu-repo/semantics/openAccessSociedade Brasileira de Pneumologia e TisiologiaJornal Brasileiro de Pneumologia v.46 n.2 20202020-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132020000200400en10.36416/1806-3756/e20190423 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Baddini-Martinez,José Ferreira,Juliana Tanni,Suzana Alves,Luis Renato Cabral Junior,Benedito Francisco Carvalho,Carlos Roberto Ribeiro Cezare,Talita Jacon Costa,Claudia Henrique da Gazzana,Marcelo Basso Jezler,Sérgio Kairalla,Ronaldo Adib Kawano-Dourado,Leticia Lima,Mariana Silva Mancuzo,Eliane Moreira,Maria Auxiliadora Carmo Rodrigues,Marcelo Palmeira Rodrigues,Silvia Carla Sousa Rubin,Adalberto Sperb Rufino,Rogério Lopes Steidle,Leila John Marques Storrer,Karin Baldi,Bruno Guedes |
spellingShingle |
Baddini-Martinez,José Ferreira,Juliana Tanni,Suzana Alves,Luis Renato Cabral Junior,Benedito Francisco Carvalho,Carlos Roberto Ribeiro Cezare,Talita Jacon Costa,Claudia Henrique da Gazzana,Marcelo Basso Jezler,Sérgio Kairalla,Ronaldo Adib Kawano-Dourado,Leticia Lima,Mariana Silva Mancuzo,Eliane Moreira,Maria Auxiliadora Carmo Rodrigues,Marcelo Palmeira Rodrigues,Silvia Carla Sousa Rubin,Adalberto Sperb Rufino,Rogério Lopes Steidle,Leila John Marques Storrer,Karin Baldi,Bruno Guedes Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology |
author_facet |
Baddini-Martinez,José Ferreira,Juliana Tanni,Suzana Alves,Luis Renato Cabral Junior,Benedito Francisco Carvalho,Carlos Roberto Ribeiro Cezare,Talita Jacon Costa,Claudia Henrique da Gazzana,Marcelo Basso Jezler,Sérgio Kairalla,Ronaldo Adib Kawano-Dourado,Leticia Lima,Mariana Silva Mancuzo,Eliane Moreira,Maria Auxiliadora Carmo Rodrigues,Marcelo Palmeira Rodrigues,Silvia Carla Sousa Rubin,Adalberto Sperb Rufino,Rogério Lopes Steidle,Leila John Marques Storrer,Karin Baldi,Bruno Guedes |
author_sort |
Baddini-Martinez,José |
title |
Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology |
title_short |
Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology |
title_full |
Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology |
title_fullStr |
Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology |
title_full_unstemmed |
Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology |
title_sort |
brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. official document of the brazilian thoracic association based on the grade methodology |
description |
ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial lung disease of unknown cause, which predominantly affects elderly men who are current or former smokers. Even though it is an uncommon disease, it is of great importance because of its severity and poor prognosis. In recent decades, several pharmacological treatment modalities have been investigated for the treatment of this disease, and the classic concepts have therefore been revised. The purpose of these guidelines was to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of IPF in Brazil. We sought to provide guidance on the practical issues faced by clinicians in their daily lives. Patients of interest, Intervention to be studied, Comparison of intervention and Outcome of interest (PICO)-style questions were formulated to address aspects related to the use of corticosteroids, N-acetylcysteine, gastroesophageal reflux medications, endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, pirfenidone, and nintedanib. To formulate the PICO questions, a group of Brazilian specialists working in the area was assembled and an extensive review of the literature on the subject was carried out. Previously published systematic reviews with meta-analyses were analyzed for the strength of the compiled evidence, and, on that basis, recommendations were developed by employing the Grading of Recommendations Assessment, Development and Evaluation approach. The authors believe that the present document represents an important advance to be incorporated in the approach to patients with IPF, aiming mainly to improve its management, and can become an auxiliary tool for defining public policies related to IPF. |
publisher |
Sociedade Brasileira de Pneumologia e Tisiologia |
publishDate |
2020 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132020000200400 |
work_keys_str_mv |
AT baddinimartinezjose brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT ferreirajuliana brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT tannisuzana brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT alvesluisrenato brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT cabraljuniorbeneditofrancisco brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT carvalhocarlosrobertoribeiro brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT cezaretalitajacon brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT costaclaudiahenriqueda brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT gazzanamarcelobasso brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT jezlersergio brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT kairallaronaldoadib brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT kawanodouradoleticia brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT limamarianasilva brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT mancuzoeliane brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT moreiramariaauxiliadoracarmo brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT rodriguesmarcelopalmeira brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT rodriguessilviacarlasousa brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT rubinadalbertosperb brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT rufinorogeriolopes brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT steidleleilajohnmarques brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT storrerkarin brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology AT baldibrunoguedes brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology |
_version_ |
1756431136285786112 |